Additional file 1 of Pembrolizumab plus azacitidine in patients with chemotherapy refractory metastatic colorectal cancer: a single-arm phase 2 trial and correlative biomarker analysis

Kuang, Chaoyuan; Park, Yongseok; Augustin, Ryan C.; Lin, Yan; Hartman, Douglas J.; Seigh, Lindsey; Pai, Reetesh K.; Sun, Weijing; Bahary, Nathan; Ohr, James; Rhee, John C.; Marks, Stanley M.; Beasley, H. Scott; Shuai, Yongli; Herman, James G.; Zarour, Hassane M.; Chu, Edward; Lee, James J.; Krishnamurthy, Anuradha

doi:10.6084/m9.figshare.17982794.v1

13148_2021_1226_MOESM1_ESM.docx (43.72 kB)

Additional file 1 of Pembrolizumab plus azacitidine in patients with chemotherapy refractory metastatic colorectal cancer: a single-arm phase 2 trial and correlative biomarker analysis

journal contribution

posted on 2022-01-07, 04:29 authored by Chaoyuan Kuang, Yongseok Park, Ryan C. Augustin, Yan Lin, Douglas J. Hartman, Lindsey Seigh, Reetesh K. Pai, Weijing Sun, Nathan Bahary, James Ohr, John C. Rhee, Stanley M. Marks, H. Scott Beasley, Yongli Shuai, James G. Herman, Hassane M. Zarour, Edward Chu, James J. Lee, Anuradha Krishnamurthy

Additional file 1. Clinical trial protocol.

Funding

National Cancer Institute Merck

History

Usage metrics

Keywords

Colorectal cancer Mismatch repair proficient Immunotherapy DNA methyltransferase inhibitor Epigenetic therapy Azacitidine Pembrolizumab PD-1 PD-L1

Licence

CC BY + CC0

Exports

RefWorks

BibTeX

Ref. manager

Endnote

DataCite

NLM

DC

Additional file 1 of Pembrolizumab plus azacitidine in patients with chemotherapy refractory metastatic colorectal cancer: a single-arm phase 2 trial and correlative biomarker analysis

Funding

National Cancer Institute Merck

History

Usage metrics

Categories

Keywords

Licence

Exports